-- 味の素(東証:2802)の親会社株主に帰属する利益は、2025年度で前年の703億円から92%増の1,347億円に急増した。 食品調味料メーカーである同社の1株当たり利益は、前年の69.77円から138.36円に増加した。これは木曜日に東京証券取引所に提出された書類で明らかになった。 3月31日終了年度の売上高は、前年の1兆5,310億円から3.5%増の1兆5,840億円となった。 同社は1株当たり24円の期末配当を発表し、6月22日から支払いを開始する。 2026年度については、親会社株主に帰属する利益を1,200億円、基本1株当たり利益を126.16円、売上高を1兆7,230億円と見込んでいる。 味の素は、今年度、中間配当と期末配当をそれぞれ1株当たり25円ずつ支払う予定であり、これは前年同期の配当額を上回る。
Related Articles
Indian Equities End Flat on Thursday as Earnings Support Offsets Weakness
Indian benchmark indices ended largely unchanged on Thursday as gains driven by earnings-related buying offset broader market weakness.The BSE Sensex fell 114.00 points, or 0.2%, to close at 77,844.52, while the NSE Nifty 50 slipped 4.30 points, or 0.02%, to settle at 24,326.65.Expectations of easing tensions between the US and Iran further supported investor sentiment. Tehran is reportedly reviewing the latest U.S. proposals aimed at ending the conflict.In corporate developments, Bharat Forge (NSE:BHARATFORG, BOM:500493) reported a decline in consolidated profit in fiscal Q4 to 2.33 billion rupees from 2.83 billion rupees a year earlier. Revenue from operations, however, rose to 20.3 billion rupees from 17.0 billion rupees.Larsen & Toubro (NSE:LT, BOM:500510) gained after its buildings and factories business secured three large orders from a real estate client for projects across three states, according to a filing. The company classifies large orders in the range of 25 billion rupees to 50 billion rupees.
Heilongjiang ZBD Pharmaceutical Wins Bids for Traditional Chinese Drug Program
Two of Heilongjiang ZBD Pharmaceutical's (SHA:603567) products won bids from China's procurement program for traditional medicines, according to a Thursday filing with the Shanghai bourse.The products include ZBD's quick-acting sugar syrup for children, indicated for fever and sore throat, and its Xiangdan injection for angina pectoris or chest pain, the filing said.
BTIG Upgrades Fortinet to Buy From Neutral, Price Target is $125
Fortinet (FTNT) has an average rating of hold and mean price target of $102.03, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)